Syantra Unveils New Path in Cancer Detection with Funding Boost
New Collaboration and Funding for Advanced Cancer Detection
Syantra Inc. has embarked on an exciting journey to enhance cancer detection through their innovative Onco-ID™ platform.
Funding to Drive Clinical Research
With the support of Alberta Innovates, Syantra is set to expand clinical studies aimed at evaluating the Onco-ID™: Breast blood test. This research targets women with elevated risk factors for breast cancer. The AICE (Accelerating Innovations into CarE) Market Access program grant will significantly supplement existing support from various entities including recent funds allocated by the Department of Defense.
Impact on the U.S. Market and FDA Compliance
This funding marks a pivotal step in Syantra’s strategic move toward FDA compliance and entering the U.S. market. The focus will be on generating vital clinical validation data, particularly for women with dense breast tissue, as well as gathering preliminary outcomes related to the Onco-ID test application.
Expert Collaboration at Mays Cancer Center
Syantra is collaborating with Dr. Jessica Treviño Jones, a respected associate professor and breast oncologist at the Mays Cancer Center. Her expertise will be crucial in enhancing the detection capabilities of the Onco-ID blood test. Dr. Jones is also the founder and director of the Cancer Risk Reduction and Education Clinic.
Excitement for Future Developments
Rob Lozuk, CEO of Syantra, expressed enthusiasm about the project's future and the opportunities that arise from the AICE grant. He stated, "We're thrilled to maximize our scientific advancements through this transformative funding, dedicated to improving early cancer detection. We anticipate significant progress in 2025, establishing many clinical pathways towards market introduction for Onco-ID."
Thriving Innovation in Alberta
Tim Murphy, Vice President of Health at Alberta Innovates, commented on Syantra's commitment to addressing real-world health challenges through innovative solutions. This partnership underscores the importance of collaborations that transcend borders, showing how Alberta’s innovators contribute to impactful healthcare advancements.
Clinical Validation and Participant Recruitment
Dr. Kristina Rinker, co-founder of Syantra, elaborated on the dual objectives of this pioneering project, aiming to recruit 500 new participants for the clinical validation study. Participation will contribute substantially to the ongoing research concerning the Onco-ID blood test for breast screening, especially among women predisposed to breast cancer.
About Syantra
Founded in Calgary by a dedicated team of leaders in biomedical engineering and clinical medicine, Syantra Inc. is poised to reshape cancer detection and management. The organization leverages cutting-edge technology with the guidance of top professionals to bring their vision to life.
Forward-Thinking Foundation and Vision
As a privately held precision biotechnology enterprise, Syantra stands at the forefront of innovation, striving to shift existing paradigms in cancer diagnostics. The company’s mission is built upon the collaboration of skilled innovators and world-renowned clinicians who are passionate about transforming patient care.
Frequently Asked Questions
What is the Onco-ID™ platform?
The Onco-ID™ platform by Syantra is a cancer detection technology that utilizes blood tests for early diagnosis, particularly focusing on breast cancer.
How will the funding be used?
The funding will support clinical studies for the Onco-ID blood test, enhancing validation data and aiding compliance for U.S. market entry.
Who is collaborating with Syantra on this project?
Syantra is working in partnership with Dr. Jessica Treviño Jones from the Mays Cancer Center, who specializes in breast oncology.
What is the goal of the clinical studies?
The studies aim to validate the Onco-ID test by recruiting participants, especially women at risk for developing breast cancer, to gather essential data.
What impact does this collaboration aim to achieve?
This collaboration seeks to advance early cancer detection techniques through innovative methodologies, potentially improving patient outcomes significantly.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.